Chart: Price Changes by Product - Text Version
Chart: Price Changes by Product, Post Blueprint Period in 2017 Compared to the Same Time Period in 2018
Research
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Prescription Drug Pricing: ASPE Resources Related to Safe Harbor Rule
Medicare Part B Drug Spending
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Medicare Part B Drugs: Pricing and Incentives
Prescription Drug Pricing Reports to Congress
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Incentivizing Generic and Biosimilar Product Uptake
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Part D Gross Drug Costs Graph - Text Version
Part D Gross Drug Costs, 2016, $US Billions
MultiSource: $42.7
Brands: $8.7
Savings: $
Single souce: $102.0
Generics: $34.0
Spending if fully substituted: $5.9
Return to the Generic and Biosimilars page .
Prescription Drugs
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Comparing Insulin Prices in the U.S. to Other Countries
Prescription Drugs: Flowchart Text Version
Pharmaceutical supply chain includes 6 parties: payers, consumers, pharmacies, pharmacy benefits manager, distributor, and drug manufacturer.
Current Estimates of Supply and Utilization of Immune Globulin Products
In February 2007, the Eastern Research Group (ERG) submitted to the Office of the Assistant Secretary for Planning and Evaluation (ASPE) Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV) (2007 report).
IGIV_Market_Update.pdf
PDF
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Endnotes
1 - Claritin, Premarin, Zantac, Prozac, Trimox, Prilosec, Lanoxin, Hydrocodone w/APAP, Norvasc, Lipitor, Furosemide, Synthroid, Coumadin, Vasotec, Atenolol, Lasix, Triamterene/HCTZ, Cardizem CD, Hydrochlorothiazide, Zestril, Prednisone, K-Dur, Zocor, Procardia XL, and Glyburide.
2 - Analysis using a different set of drugs might yield different r
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Cash Share of the Market
Cash payments have accounted for a declining share of the retail market for prescription drugs, as noted in Chapter 3. The share of prescriptions for which the purchaser pays in cash at the time of the transaction has declined from 63 percent in 1990 to 25 percent in 1998. 4 One possible explanation for some of the differences just observed could
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Prescription Drug Prices
Given the national nature of many of the major players in the prescription drug market—drugs are produced by national manufacturers, distributed through mostly national PBMs and in many cases through national pharmacy chains—we might not expect to see large price differences by region. We would expect to see small differences based on local pr
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Utilization and Spending
In Chapter 2, various data were presented that showed spending differences between individuals with and without insurance coverage for prescription drugs. Here we consider those same comparisons within regions. Because size of prescription may vary due to differences in local medical practice patterns and variations in state Medicaid regulations o
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Coverage
Table C-1 shows variation in coverage levels by region using MEPS data on drug coverage for the civilian, noninstitutionalized population. The highest coverage rates are in the Midwest and Northeast with the lowest coverage rate in the South. The pattern observed is similar to analyses of general health insurance coverage elsewhere.
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Appendix C. State and Regional Variations
One area of inquiry that is not discussed in the main report is regional and state variation. Preliminary analysis from several different sources suggests that there are substantial regional and state variations in spending and utilization of prescription drugs and in prices faced by consumers. At this point, we can observe some differences, but w
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Endnotes
1 - The one exception was Medicare HMO coverage, which was identified through HCFA(now known as CMS) enrollment records.
2 -The MEPS estimates are adjusted for two reasons. First, the adjusted MEPS estimates can be directly compared to the MCBS estimates. Second, the unadjusted MEPS estimates would overstate the percentage of beneficiaries who h
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. MEPS Price Data
It should be emphasized that, while some aspects of the MEPS method of assigning coverage may introduce potential biases into its estimates of relative utilization by covered and noncovered beneficiaries, there is no reason to believe that chapter 3 overstates the price differences for the two groups. It was noted earlier that, while MEPS treats a
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Effects of Coverage Estimates
As was discussed earlier, MEPS produces higher estimates of Medicare beneficiaries who had drug coverage than MCBS for three basic reasons. First, MEPS assigns coverage to larger numbers of people who did not report having drug coverage but who were found to have a third-party payment for a prescription. Second, MEPS treats all Medicaid and Medica
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Spending Estimates
MEPS data for 1996 indicate that 27 percent of people who used prescription drugs paid for those drugs in full at the time they received them. 3 Most people with public or private coverage pay only a copayment or coinsurance amount. (Exceptions include people who have not yet met a deductible or who have exceeded a cap on their coverage and peopl
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices.. Utilization Estimates
The MCBS and the MEPS household component both involve multiple rounds of interviews with each respondent. In each interview, the respondent is asked about services used in the period since the last interview. MEPS separately surveys pharmacies named by respondents, and can thus supplement the information gathered in the household survey. Because